MapLight Therapeutics chief scientific officer sells $93,025 in shares

MapLight Therapeutics CEO Lillie James Woodruff recently sold 11,513 shares of the company on October 15, 2026, for $93,025. The transaction occurred as the stock price hovered near its 52-week low of $7.46, currently trading at $7.70, marking an 81% decline from its 52-week high of $40.43. This sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, not a discretionary move by Woodruff.

Her stake in the company now stands at 198,597 shares following the sale. Meanwhile, MapLight Therapeutics has recently secured a $150 million private placement financing and received mixed analyst ratings after its Q2 2026 earnings report, with some analysts lowering their price targets due to dilution concerns and trial data results.